A phase 1 clinical trial of SP16, a first-in-class anti-inflammatory LRP1 agonist, in healthy volunteers.

A phase 1 clinical trial of SP16, a first-in-class anti-inflammatory LRP1 agonist, in healthy volunteers.

<h4>Background</h4>Endogenous serine protease inhibitors are associated with anti-inflammatory and pro-survival signaling mediated via Low-density lipoprotein receptor-related protein 1 (LRP1) signaling. SP16 is a short polypeptide that mimics the LRP1 binding portion of alpha-1 antitryp...

Full description

Saved in:
Bibliographic Details
Main Authors: George F Wohlford, Leo F Buckley, Dinesh Kadariya, Taeshik Park, Juan Guido Chiabrando, Salvatore Carbone, Virginia Mihalick, Matthew S Halquist, Adam Pearcy, Dana Austin, Cohava Gelber, Antonio Abbate, Benjamin Van Tassell
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0247357&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0247357&type=printable

Similar Items